PriceTargets.com logo

bioMérieux - BMXMF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$103.17 As of 04/18/2024 03:51 PM ET
▼ -7.8276 (-7.05%)

This chart shows the closing price for BMXMF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New bioMérieux Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMXMF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMXMF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for bioMérieux in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $103.17.

This chart shows the closing price for BMXMF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in bioMérieux. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/29/2023HSBCUpgradeHold ➝ Buy
5/3/2023HSBCUpgradeReduce ➝ Hold
12/21/2022Societe GeneraleUpgradeHold ➝ Buy
12/16/2022Berenberg BankBoost TargetHold ➝ Hold€89.70 ➝ €92.50
11/8/2022Berenberg BankLower TargetHold ➝ Hold€110.00 ➝ €89.70
10/27/2022Morgan StanleyBoost TargetOverweight ➝ Overweight€108.00 ➝ €109.00
10/18/2022Morgan StanleyInitiated CoverageOverweight
9/2/2022Societe GeneraleDowngradeBuy ➝ Hold
12/22/2021AlphaValueUpgradeReduce
10/27/2021Exane BNP ParibasUpgradeUnderperform ➝ Outperform
6/11/2021Berenberg BankUpgradeSell ➝ Hold
3/1/2021Morgan StanleyReiterated RatingOverweight
2/25/2021Societe GeneraleReiterated RatingBuy
2/19/2021Berenberg BankDowngradeHold ➝ Sell
12/10/2020BNP ParibasDowngradeNeutral ➝ Underperform
12/10/2020Exane BNP ParibasDowngradeNeutral ➝ Underperform
12/9/2020Morgan StanleyInitiated CoverageOverweight
10/23/2020Societe GeneraleUpgradeHold ➝ Buy
9/23/2020Berenberg BankReiterated RatingHold
7/13/2020Societe GeneraleDowngradeBuy ➝ Hold
4/30/2020Berenberg BankReiterated RatingHold
(Data available from 4/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
bioMérieux logo
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Read More

Today's Range

Now: $103.17
Low: $103.17
High: $105.56

50 Day Range

MA: $109.56
Low: $102.85
High: $113.38

52 Week Range

Now: $103.17
Low: $90.23
High: $115.25

Volume

221 shs

Average Volume

154 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of bioMérieux?

The following equities research analysts have issued research reports on bioMérieux in the last year: HSBC Holdings plc.
View the latest analyst ratings for BMXMF.

What is the current price target for bioMérieux?

0 Wall Street analysts have set twelve-month price targets for bioMérieux in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for bioMérieux in the next year.
View the latest price targets for BMXMF.

What is the current consensus analyst rating for bioMérieux?

bioMérieux currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BMXMF will outperform the market and that investors should add to their positions of bioMérieux.
View the latest ratings for BMXMF.

What other companies compete with bioMérieux?

Other companies that are similar to bioMérieux include Shionogi & Co., Ltd., Eurofins Scientific, Sysmex, Eisai and Ramsay Health Care. Learn More about companies similar to bioMérieux.

How do I contact bioMérieux's investor relations team?

bioMérieux's physical mailing address is 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280. The company's listed phone number is 33-04-78-87-20-00 and its investor relations email address is [email protected]. The official website for bioMérieux is www.biomerieux.com. Learn More about contacing bioMérieux investor relations.